(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 February 2008 (28.02.2008)

PCT

(10) International Publication Number
WO 2008/023161 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/519* (2006.01)

(21) International Application Number:
PCT/GB2007/003179

(22) International Filing Date: 21 August 2007 (21.08.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/823,311	23 August 2006 (23.08.2006)	US
60/938,776	18 May 2007 (18.05.2007)	US

(71) Applicant *(for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM only)*: **KUDOS PHARMACEUTICALS LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London, W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DUGGAN, Heather, Mary, Ellen** [GB/GB]; KuDOS Pharmaceuticals Limited, 26 Foundry Lane, Horsham, Sussex, RH13 5PX (GB). **LEROUX, Frederic Georges Marie** [FR/GB]; KuDOS Pharmaceuticals Limited, 26 Foundry Lane, Horsham, Sussex, RH13 5PX (GB). **MALAGU, Karine** [FR/GB]; KuDOS Pharmaceuticals Limited, 26 Foundry Lane, Horsham, Sussex, RH13 5PX (GB). **MARTIN, Niall, Morrisson, Barr** [GB/GB]; KuDOS Pharmaceuticals Limited, 410 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PE (GB). **MENEAR, Keith, Allan** [GB/GB]; KuDOS Pharmaceuticals Limited, 26 Foundry Lane, Horsham, Sussex, RH13 5PX (GB). **SMITH, Graeme, Cameron, Murray** [GB/GB]; KuDOS Pharmaceuticals Limited, 410 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PE (GB).


(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-SE-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(54) Title: 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS



(I)

(57) Abstract: There is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula (1), and the use of a compound of Formula (1) as a medicament and in the treatment of cancer.

WO 2008/023161 A1